Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company headquartered in Redwood City, California, focused on discovering and developing medications that modulate the hormone cortisol to treat severe endocrine, oncologic, metabolic, and neurologic disorders. The company's flagship product, Korlym (mifepristone), has been sold in the United States since 2012 for endogenous Cushing's syndrome, and an authorized generic version launched in June 2024.
Corcept expanded into oncology in 2026 when the FDA approved Lifyorli (relacorilant), used in combination with nab-paclitaxel for platinum-resistant ovarian cancer; the therapy launched commercially on April 1, 2026 and has been added to NCCN guidelines as a preferred regimen. The company also maintains a broad pipeline of selective cortisol modulators, including relacorilant for hypercortisolism, miricorilant for metabolic dysfunction-associated steatohepatitis, and dazucorilant for ALS. Investors follow CORT closely because of its rapid revenue growth, oncology expansion, and several pending regulatory and clinical milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, CORT has declined approximately 38%, falling from a closing price of $116.23 on October 14 to about $71.89 in mid-November. The decline was not gradual: the stock dropped roughly 20% in a single session on October 23, 2026, one of its sharpest one-day moves on record, before stabilizing near the low-$70s.
The quarterly picture shows a similar downward trajectory over a longer horizon. Over the last three months, CORT is down roughly 35%, falling from about $110 in mid-August to current levels. The stock reached its 52-week high of $126.38 on August 25, 2026, meaning the shares have pulled back more than 40% from that peak. In other words, the 30-day move is part of a broader multi-month reversal that began shortly after the stock set record highs in late summer.
Several overlapping factors pressured the stock during the most recent 30-day window. The steepest decline came on October 22–23, when shares fell more than 20% in a single session. Analysts and market data pointed to profit-taking after a long run-up, ongoing concerns about generic erosion of Korlym, unusually heavy insider selling, and a valuation that had become demanding relative to peers. Broader market conditions also played a role, as small- and mid-cap biotechnology names were dragged lower amid renewed inflation and rate concerns.
Then, on November 3, Corcept reported third-quarter results that beat expectations on both revenue and earnings — revenue of $340.5 million and adjusted EPS of $1.01 versus a $0.79 consensus. Despite the strong quarter, shares fell roughly 4% in after-hours trading because management reiterated, rather than raised, full-year 2026 revenue guidance of $1.1 billion to $1.2 billion. Piper Sandler reaffirmed an Overweight rating and raised its price target to $173, but the wider analyst community remains split, with targets ranging from about $50 (Wolfe Research) to $165 (H.C. Wainwright and Truist), and Zacks cutting its rating from Strong Buy to Hold in late October. Persistent insider selling — no insider purchases and dozens of sales over the prior six months — further dampened investor confidence.
The three-month trend reflects a sharp reversal after a period of exceptional gains. Through late August, CORT was among the market's standout performers, climbing to a 52-week high of $126.38 on August 25, 2026, driven by enthusiasm around the Lifyorli launch, the relacorilant resubmission, and strong Cushing's franchise growth. From that peak, momentum faded as investors weighed the stock's rich valuation, persistent insider sales, and the competitive risk to Korlym from authorized generics.
Negative research commentary added pressure, including a bearish "Underperform" note from StockStory in early October that cited structural concerns about sales growth trends and contracting margins. A leadership transition — the announced retirement of the President of Endocrinology — contributed to uncertainty in September. While the company's fundamentals remained solid through the period, with Lifyorli uptake exceeding 2,300 treated patients and third-quarter revenue rising 64% year over year, the market's focus shifted from growth to the sustainability of that growth and the absence of a guidance raise, producing the multi-month drawdown.
The most important near-term catalyst is the FDA's December 17, 2026 target action date for Corcept's resubmitted relacorilant NDA in Cushing's syndrome. A favorable decision would expand the company's endocrinology franchise, while a setback could pressure the shares further. Investors should also monitor the ongoing Lifyorli launch trajectory, the competitive dynamics surrounding Korlym and its authorized generic, and whether management raises full-year guidance in subsequent quarters.
Beyond those company-specific items, watch analyst rating and price-target revisions, the pace of insider selling, and broader macro conditions affecting small- and mid-cap biotech valuations. Finally, additional clinical readouts, including data from the BELLA program in ovarian cancer and pipeline assets in MASH and ALS, will help shape the longer-term narrative. These factors should be evaluated objectively, without treating them as a basis for any specific investment decision.
In my analysis of names like CORT, I often turn to Tickeron’s AI Trading Bots to test automated strategies against similar volatility patterns. The platform’s selection of bots covers a range of timeframes and risk levels, which helps me compare how different quantitative approaches might respond to events like earnings or regulatory decisions. It is a useful way to add data-driven perspective without replacing my own review of fundamentals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CORT saw its Momentum Indicator move below the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 55 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 65%.
The Moving Average Convergence Divergence Histogram (MACD) for CORT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 22 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
CORT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CORT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for CORT entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 277 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CORT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.146) is normal, around the industry mean (3.592). CORT's P/E Ratio (137.302) is considerably higher than the industry average of (-1.190). Projected Growth (PEG Ratio) (2.660) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (15.898) is also within normal values, averaging (442.120).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of drugs for the treatment of severe psychiatric and neurological diseases
Industry Biotechnology